The IPO is now live and will likely price within 1-2 days. Traders should watch for the final pricing and any indication of demand. Given the tiny market cap and pre-revenue status, the stock is highly speculative and prone to extreme volatility post-IPO.
Price Chart
Executive Summary
The SEC declared effective FibroBiologics' S-1 registration statement (File No. 333-297353) on July 16, 2026, enabling the company to proceed with its IPO of up to 1,136,363 shares of common stock and accompanying warrants at an assumed combined price of $4.40 per unit.
Key Facts
- S-1 registration declared effective on July 16, 2026
- Offering includes up to 1,136,363 shares of common stock and up to 1,136,363 warrants to purchase common stock
- Assumed combined public offering price of $4.40 per unit
- Offering also includes up to 1,136,363 pre-funded warrants and up to 79,545 placement agent warrants
- H.C. Wainwright & Co. is the exclusive placement agent
- Offering will terminate on April 7, 2026, unless earlier terminated by the company
- Company has a $5M market cap and is a pre-revenue clinical-stage biotech
Financial Impact
Up to ~$5M gross proceeds at $4.40/unit before underwriting discounts and expenses, assuming full exercise of warrants. Dilution of up to ~2.3M shares (including warrants) on a current market cap of $5M.
Risk Factors
- Extreme dilution from the offering and warrants
- Pre-revenue clinical-stage biotech with no approved products
- Very low market cap ($5M) makes stock highly volatile and illiquid
- Offering termination date is April 7, 2026 — if not completed, the stock may face additional pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002341 |
| Document: 9999999995-26-002341-index.html | 9999999995-26-002341 |
| Document: 9999999995-26-002341.txt | 9999999995-26-002341 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers